StreetInsider.com News Articles

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

The analyst comments "Downgrading to Neutral following agreement to be acquired by Eli Lilly; lowering our price target to $7.50 from $25. On July 16, AtaiBeckley announced that it entered into a definitive agreement to be acquired by Eli Lilly (LLY; not rated) in a transaction valued at up to approximately $3.8 billion. Lilly will acquire all outstanding AtaiBeckley shares for $6.75 per share in cash upon closing, plus a contingent value right (CVR)

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral

Tue, 21 Jul 2026 06:45:05 -0400

(Updated - July 21, 2026 6:45 AM EDT)

H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral with a price target of $7.50.

Berenberg Downgrades AtaiBeckley Inc (ATAI) to Hold

Mon, 20 Jul 2026 05:26:41 -0400

Berenberg analyst Harry Gillis downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $7.22 yesterday.

TD Cowen Downgrades AtaiBeckley Inc (ATAI) to Hold

Fri, 17 Jul 2026 17:06:16 -0400

TD Cowen analyst Ritu Baral downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $7.15 yesterday.

Jefferies Downgrades AtaiBeckley Inc (ATAI) to Hold

Fri, 17 Jul 2026 03:35:52 -0400

Jefferies analyst Andrew Tsai downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold with a price target of $7.50 (from $10.00).

The analyst comments: “Expected to close Q3, LLY will acquire ATAI for $6.75/sh ($2.8B in equity) plus a $2.50/sh CVR (another ~$1B). We think the deal heavily favors LLY, as ATAI's lead asset BPL-003 (intranasal 5-MeO-DMT) should have multi billion dollar peak sales potential. At the same time, we appreciate LLY has significantly more resources to maximize the long-term value of ATAI's psychedelic assets. In any case, the deal has (+) implications for the entire psychedelic space.”

For an analyst ratings

Jefferies Downgrades AtaiBeckley Inc (ATAI) to Hold

Fri, 17 Jul 2026 03:35:52 -0400

Jefferies analyst Andrew Tsai downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold with a price target of $7.50 (from $10.00).

For an analyst ratings

Jones Trading Downgrades AtaiBeckley Inc (ATAI) to Hold

Thu, 16 Jul 2026 16:15:56 -0400

Jones Trading analyst Justin Walsh downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Canaccord Downgrades AtaiBeckley Inc (ATAI) to Hold

Thu, 16 Jul 2026 15:36:26 -0400

Canaccord analyst Sumant Kulkami downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold with a price target of $8.00.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Guggenheim Downgrades AtaiBeckley Inc (ATAI) to Neutral

Thu, 16 Jul 2026 14:07:08 -0400

Guggenheim analyst Eddie Hi downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Neutral.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Maxim Group Downgrades AtaiBeckley Inc (ATAI) to Hold

Thu, 16 Jul 2026 12:54:10 -0400

Maxim Group analyst Michael Okunewitch downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Cantor Fitzgerald Downgrades AtaiBeckley Inc (ATAI) to Neutral

Thu, 16 Jul 2026 11:53:47 -0400

Cantor Fitzgerald analyst Pete Stavropoulos downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Overweight to Neutral.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'

Thu, 16 Jul 2026 10:00:57 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).

The analyst comments "We view LLY's acquisition of ATAI for ~$3.8B total equity value as validating our conviction in the transformative potential of psychedelic medicine. We see unique advantages for the shorter-acting MOAs of BPL-003 (5-MeO-DMT) and VLS-01, for which we imagine operational synergies for a large pharma that could most readily leverage commercial infrastructure to accelerate uptake. Deal terms include ~$2.8B upfront reflecting a $6.75/share value plus ~$1B in CVRs including: 1) $1.00/share upon initiating a Ph3 study for VLS-01 within 4 years

Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'

Thu, 16 Jul 2026 10:00:57 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).

Needham Downgrades AtaiBeckley Inc (ATAI) to Hold

Thu, 16 Jul 2026 09:27:41 -0400

Needham analyst Ami Fadia downgraded AtaiBeckley Inc (NASDAQ: ATAI) from Buy to Hold.

For an analyst ratings summary and ratings history on AtaiBeckley Inc click here. For more ratings news on AtaiBeckley Inc click here.

Shares of AtaiBeckley Inc closed at $5.36 yesterday.

Why Psychedelic stocks are surging today

Thu, 16 Jul 2026 07:17:49 -0400

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.

AtaiBeckley shares are up 30.8% premarket, while Compass Pathways is up 7.4% and GH Research is up 18.9%.

Under the deal, Lilly will acquire all outstanding AtaiBeckley shares for $6.75 per share in cash, plus up to $2.50 per share through a Contingent Value Right tied to development and regulatory milestones for AtaiBeckley's lead programs, BPL-003 and VLS-01.

The upfront cash consideration represents an aggregate equity value of

Why Psychedelic stocks are surging today

Thu, 16 Jul 2026 07:17:49 -0400

AtaiBeckley shares are up 30.8% premarket, while Compass Pathways is up 7.4% and GH Research is up 18.9%.

The upfront cash consideration represents an aggregate equity value of

Why Psychedelic stocks are surging today

Thu, 16 Jul 2026 07:17:49 -0400

AtaiBeckley shares are up 30.8% premarket, while Compass Pathways is up 7.4% and GH Research is up 18.9%.

The upfront cash consideration represents an aggregate equity value of

Why Psychedelic stocks are surging today

Thu, 16 Jul 2026 07:17:49 -0400

AtaiBeckley shares are up 30.8% premarket, while Compass Pathways is up 7.4% and GH Research is up 18.9%.

The upfront cash consideration represents an aggregate equity value of

Eli Lilly to acquire AtaiBeckley for up to $3.8B

Thu, 16 Jul 2026 06:45:23 -0400

Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.

Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion.

Eli Lilly to acquire AtaiBeckley for up to $3.8B

Thu, 16 Jul 2026 06:45:23 -0400

Eli Lilly to acquire AtaiBeckley for up to $3.8B

Thu, 16 Jul 2026 06:45:23 -0400

Eli Lilly to acquire AtaiBeckley for up to $3.8B

Thu, 16 Jul 2026 06:45:23 -0400

Eli Lilly to acquire AtaiBeckley for up to $3.8B

Thu, 16 Jul 2026 06:45:23 -0400